Glaser Weil’s corporate attorneys serve a broad spectrum of publicly and privately held companies — from family businesses, start-ups and emerging growth enterprises to large global corporations with household names. Our client portfolio extends across diverse industries, encompassing entertainment, hospitality, oil and gas, software, life sciences, sports, manufacturing, retail, consumer products and more.

Our attorneys seamlessly navigate both the boardroom and the negotiating table, offering strategic counsel across a broad spectrum of issues related to business formation, operation, expansion and disposition. Whether orchestrating intricate transactions or addressing everyday management concerns, we skillfully cater to the complete range of our clients' corporate needs.

We approach each client engagement proactively and creatively. We invest time to learn your business and the unique challenges within your industry, as a deep understanding is foundational to our successful representation. Our collaborative and multidisciplinary approach enables us to resolve your issues adeptly. When your needs extend beyond our core expertise, we leverage the skills and resources of colleagues in our litigation, real estate, intellectual property and industry practices to provide swift problem-solving.

We recognize that sustained success hinges on seamless, ongoing collaboration and have cultivated many enduring client relationships. Our clients’ success is our success. We are committed to applying a game-changing standard of excellence to deliver unparalleled legal solutions and drive our clients' success to new heights.

Who We Represent

  • Global corporations
  • Emerging growth companies
  • Family businesses

What We Do

  • Corporate governance
  • Entity formation
  • Fund formation
  • Fundraising
  • General corporate transactions
  • Loan documentation
  • Mergers and acquisitions
  • Public offerings
  • Securities law compliance and public reporting
  • SPAC and reverse merger transactions
  • Tax and executive compensation

Our Team


  • Carl Zeiss Meditec AG in connection with its proposed $1.6 billion acquisition of a division of Bausch & Lomb.
  • waste disposal company with an enterprise value in excess of $1.4 billion in connection with its sale. Targeted sales price $850 million.
  • Wyatt Technology in its $1.36 billion acquisition by Waters Corporation (NYSE: WAT), a global pharmaceutical leader in analytical instruments and software.
  • An industrial software company in its $1 billion sale to a publicly traded Swedish engineering company.
  • minority owner of the New York Yankees in connection with its sale which, at the time, was the highest price per unit in the history of the New York Yankees and no investment banker was involved.
  • Part of the ownership group in connection with the acquisition of the Sacramento Kings for $500 million.
  • MaxIT, a Riordan, Lewis & Haden portfolio company, in connection with its sale to SAIC for $500 million. Targeted sales price approximately $300 million.
  • The ownership group in connection with the acquisition of the New Orleans Hornets for $350 million.
  • Representation of software company in its sale for $320 million. Targeted sales price $220 million.
  • An online and mobile prepared food ordering and delivery company in a $308 million de-SPAC transaction and $75 million convertible note PIPE.
  • Representation of medical device company in its sale for $300 million. Original offered purchase price $225 million.
  • American Title, a publicly traded (NASDAQ) title insurance company, in its $182 million merger with Fidelity Title.
  • Alacer Corporation (manufacturer of Emergen-C) in connection with its sale to Pfizer, helping to achieve a sale price 40% above initial estimates.
  • Equityholders of Blackstone Consulting, Inc. andJ.B. Properties, Inc. in the sale of 49% of their interests in the companies to USAGM Acquisition, LLC.
  • Alumni Capital Management, an alternative investment manager, in the $10 million equity financings of Motorsport Games Inc. (NASDAQ: MSGM) and NeuBase Therapeutics Inc. (NASDAQ: NBSE).
  • Green Hygienics Holdings, Inc., in a $25 million registered equity financing.
  • TriMed Inc., a global developer of market-leading orthopedic implants, in the sale of a majority interest to Henry Schein, Inc. (NASDAQ: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners.
  • Horizon/CJK in its joint venture with Fortress Investment Group to acquire United Oil Co.
  • INVO Bioscience, Inc. (Nasdaq: INVO), a global leader in expanding access to advanced fertility treatment, in an all-stock reverse merger agreement with NAYA Biosciences Inc.
  • A pair of California-based recycling and diversion companies that specialize in the collection and processing of waste in their sale to a private equity firm, exceeding $1 billion.
  • SC Fuels, a leading petroleum distributor, in its swap of United Fuel & Energy in exchange for Pilot Energy’s California land-based business and southwest operations.
  • A super-grid company in financings related to a large-scale alternative energy telecommunications, infrastructure and manufacturing project.
  • Public pension funds in the formation of more than 250 private equity entities.

Select Clients

  • Alliant Capital
  • Alumni Capital Management
  • Blackstone Consulting
  • Green Hygienics Holdings
  • INVO Bioscience, Inc.
  • SC Fuels
  • Wyatt Technology


Awards and Recognition

Key Contacts

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.